5AM Ventures

5AM Ventures is a venture capital firm founded in 2002, focusing on building next-generation life science companies. With offices in San Francisco and Boston, the firm invests in private therapeutic companies, emphasizing Series A rounds. Their portfolio spans biopharmaceuticals, drug delivery technologies, and life science instruments. The firm employs a hands-on approach, often partnering closely with entrepreneurs and academics to establish proof-of-concept data, facilitating successful Series A financings. Since inception, 5AM Ventures has raised over $2 billion in capital, supporting more than 100 public and private companies. Their investment strategy includes the 4:59 Initiative, an internal platform designed to discover, incubate, and fund transformative scientific ideas. This initiative allows 5AM Ventures to proactively seek out academic researchers and visionary entrepreneurs, often embedding themselves as active members of the operating team. By bridging the gap from concept to company, they accelerate the translation of groundbreaking science into real-world solutions. The firm's recent investments include Ensoma, CAMP4 Therapeutics, and Surrozen, reflecting their commitment to advancing healthcare through innovative life science ventures.